布地奈德缓释胶囊治疗免疫球蛋白A肾病的研究进展  

Progress in the treatment of immunoglobulin A nephropathy with budesonide extended-release capsules

作　　者：刘洋[1,2] 靳盼盼 邱博 吴惠珍[1,2] LIU Yang;JIN Panpan;QIU Bo;WU Huizhen(Graduate School of Hebei Medical University,Shijiazhuang 050017,Hebei,China;Department of Pharmacy,Hebei General Hospital,Hebei Key Laboratory of Clinical Pharmacy,Shijiazhuang 050051,Hebei,China)

机构地区：[1]河北医科大学研究生学院,河北石家庄050017 [2]河北省人民医院药学部,河北省临床药学重点实验室,河北石家庄050051

出　　处：《中国临床药理学与治疗学》2024年第9期1062-1069,共8页Chinese Journal of Clinical Pharmacology and Therapeutics

基　　金：河北省自然科学基金青年基金项目(H2020307020)。

摘　　要：免疫球蛋白A肾病是一种常见的自身免疫性肾病。越来越多的研究表明,免疫球蛋白A肾病可能与黏膜免疫系统功能障碍有关。免疫球蛋白A肾病是以半乳糖缺陷型IgA1免疫复合物的系膜沉积为特征,这种半乳糖缺陷型IgA1被认为起源于黏膜上的B细胞,而B细胞大量存在于富含派尔集合淋巴结的远端回肠中。布地奈德新型靶向释放制剂已被证明可以将药物输送到远端回肠,目的是将免疫球蛋白A肾病患者的不良事件降至最低。本文对布地奈德缓释胶囊的作用机制、剂型特点、临床研究、药物相互作用和不良事件以及局限性等进行综述。Immunoglobulin A nephropathy is a common autoimmune nephropathy.A growing body of research suggests that immunoglobulin A nephropathy may be associated with dysfunction of the mucosal immune system.Immunoglobulin A nephropathy is characterized by thylakoid deposition of galactose-deficient IgA1 immune complexes,which are thought to originate from mucosal Bcells,which are abundantly present in the distal ileum,which is rich in Pyle's collecting lymph nodes.A novel targeted release formulation of budesonide has been shown to deliver the drug to the distal ileum with the aim of minimizing adverse events in patients with immunoglobulin A nephropathy.This article reviews the mechanism of action,dosage form characteristics,clinical studies,drug interactions and adverse events,and limitations of budesonide extended-release capsules.

关 键 词：布地奈德缓释胶囊 免疫球蛋白A肾病 TARGIT技术 临床研究 

分 类 号：R692.6[医药卫生—泌尿科学] R969[医药卫生—外科学]